利亞德(300296.SZ):AR眼鏡我們主要是通過與Saphlux合作
格隆匯5月6日丨利亞德(300296.SZ)在投資者互動平台表示,公司首款交互式Mini AI 全息玩具,依託利亞德在數字人技術、數字內容創作、先進顯示技術及多模態交互等領域的核心優勢,是目前行業內唯一不懼反射炫光的產品。AR眼鏡我們主要是通過與 Saphlux 合作,推出了基於單色 Micro LED 光機的 AR 眼鏡產品,通過參股的方式聯合Saphlux 開發並推向市場。產品上市前需要進行銷售內測,面市時間及方式待定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.